Venetoclax in adult acute myeloid leukemia
Venetoclax is a potent inhibitor that specifically targets B-cell lymphoma-2 (BCL-2), which has been demonstrated to be effective in preclinical studies utilizing acute myeloid leukemia (AML) cell lines and xenograft models. Significant antileukemic activity was also observed in clinical trials, bot...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-12-01
|
| Series: | Biomedicine & Pharmacotherapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332223016189 |
| _version_ | 1797630631683817472 |
|---|---|
| author | Mengci Hu Wenzhe Li Youshan Zhang Caixia Liang Jie Tan Ya Wang |
| author_facet | Mengci Hu Wenzhe Li Youshan Zhang Caixia Liang Jie Tan Ya Wang |
| author_sort | Mengci Hu |
| collection | DOAJ |
| description | Venetoclax is a potent inhibitor that specifically targets B-cell lymphoma-2 (BCL-2), which has been demonstrated to be effective in preclinical studies utilizing acute myeloid leukemia (AML) cell lines and xenograft models. Significant antileukemic activity was also observed in clinical trials, both as a monotherapy and in combination with other drugs. This novel therapeutic approach has revolutionized the treatment prospects for AML patients with unfavorable prognoses and those who are unable to tolerate intensive chemotherapy. Nevertheless, further investigations are required to establish the optimal dosing, sequencing, and combinational strategies of venetoclax for AML treatments. Additionally, identifying biomarkers is crucial for predicting response and resistance to this targeted intervention. In this review, we provide an overview of venetoclax-based therapy for AML and explore potential avenues for future research. |
| first_indexed | 2024-03-11T11:10:54Z |
| format | Article |
| id | doaj.art-beef020d16a54cef94676e895f292560 |
| institution | Directory Open Access Journal |
| issn | 0753-3322 |
| language | English |
| last_indexed | 2024-03-11T11:10:54Z |
| publishDate | 2023-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Biomedicine & Pharmacotherapy |
| spelling | doaj.art-beef020d16a54cef94676e895f2925602023-11-12T04:39:26ZengElsevierBiomedicine & Pharmacotherapy0753-33222023-12-01168115820Venetoclax in adult acute myeloid leukemiaMengci Hu0Wenzhe Li1Youshan Zhang2Caixia Liang3Jie Tan4Ya Wang5Department of Hematology, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, ChinaDepartment of Endocrinology, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, ChinaDepartment of Hematology, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, ChinaDepartment of Hematology, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, ChinaDepartment of Hematology, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, China; Corresponding author.Department of Endocrinology, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, China; Department of Hubei Provincial Clinical Research Center for Personalized Diagnosis and Treatment of Cancer, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, China; Corresponding author at: Department of Endocrinology, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, China.Venetoclax is a potent inhibitor that specifically targets B-cell lymphoma-2 (BCL-2), which has been demonstrated to be effective in preclinical studies utilizing acute myeloid leukemia (AML) cell lines and xenograft models. Significant antileukemic activity was also observed in clinical trials, both as a monotherapy and in combination with other drugs. This novel therapeutic approach has revolutionized the treatment prospects for AML patients with unfavorable prognoses and those who are unable to tolerate intensive chemotherapy. Nevertheless, further investigations are required to establish the optimal dosing, sequencing, and combinational strategies of venetoclax for AML treatments. Additionally, identifying biomarkers is crucial for predicting response and resistance to this targeted intervention. In this review, we provide an overview of venetoclax-based therapy for AML and explore potential avenues for future research.http://www.sciencedirect.com/science/article/pii/S0753332223016189Acute myeloid leukemiaVenetoclaxCombinatorial regimens |
| spellingShingle | Mengci Hu Wenzhe Li Youshan Zhang Caixia Liang Jie Tan Ya Wang Venetoclax in adult acute myeloid leukemia Biomedicine & Pharmacotherapy Acute myeloid leukemia Venetoclax Combinatorial regimens |
| title | Venetoclax in adult acute myeloid leukemia |
| title_full | Venetoclax in adult acute myeloid leukemia |
| title_fullStr | Venetoclax in adult acute myeloid leukemia |
| title_full_unstemmed | Venetoclax in adult acute myeloid leukemia |
| title_short | Venetoclax in adult acute myeloid leukemia |
| title_sort | venetoclax in adult acute myeloid leukemia |
| topic | Acute myeloid leukemia Venetoclax Combinatorial regimens |
| url | http://www.sciencedirect.com/science/article/pii/S0753332223016189 |
| work_keys_str_mv | AT mengcihu venetoclaxinadultacutemyeloidleukemia AT wenzheli venetoclaxinadultacutemyeloidleukemia AT youshanzhang venetoclaxinadultacutemyeloidleukemia AT caixialiang venetoclaxinadultacutemyeloidleukemia AT jietan venetoclaxinadultacutemyeloidleukemia AT yawang venetoclaxinadultacutemyeloidleukemia |